Moderna’s personalised mRNA cancer vaccine met key goals in a Phase 3 melanoma trial, triggering a sharp stock rally and boosting hopes for mRNA-based cancer treatments beyond COVID-19.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.